Matt Kaeberlein
Matt Kaeberlein is a professor at the University of Washington and a co-founder of the Dog Aging Project, the largest study of canine health and aging ever undertaken. His research focuses on understanding how genetics, lifestyle, and environmental factors influence the longevity and health of dogs, with the aim of extending their lifespan and improving their quality of life. Kaeberlein is also involved in clinical trials testing the potential anti-aging drug rapamycin on dogs, seeking to discover ways to slow down the aging process in pets.
Not in the pool (under ¢1).
Recent news mentions
Matt Kaeberlein is an affiliate professor at the University of Washington who has studied NAD+ but was not involved in the new research.
New research upends the argument for a popular longevity supplement
New Zealand· 2026-05-28
Matt Kaeberlein is an expert in healthy aging who collaborated on the Dog Aging Project.
Was die Forschung an Hunden uns Menschen bringt
Switzerland· 2025-10-04
Matt Kaeberlein commented on the importance of rigorous testing for lithium treatments for Alzheimer's.
Lítio pode ser chave para reverter Alzheimer, aponta pesquisa
Liechtenstein· 2025-09-25
Matt Kaeberlein is a longevity researcher who conducted a self-experiment with Rapamycin.
Können Rapamycin und Metformin das Altern stoppen?Switzerland· 2025-08-26
Matt Kaeberlein is an American biologist who criticized Sinclair's claims about anti-ageing supplements.
Harvard Medical School professor David Sinclair’s anti-ageing quest
Australia· 2025-06-13
Matt Kaeberlein is the co-founder of the Dog Aging Project and explains the components of the study.
The project seeking to extend the lifespan of man’s best friendAustralia· 2025-05-17
